According to the cBioPortal for cancer genomics data (https://www.cbioportal.org/index.do), the frequency of EVI1 genetic alteration was lower in glioma (2.1% of 283 cases) than in other solid cancers (lung squamous cell carcinoma, 44.1%; ovarian serous cyst adenoma, 33.8%; esophageal carcinoma, 25.5%; and neuroendocrine prostate cancer, 22.4%). The gene discussed is MECOM; the disease is glioma.